• This email address is being protected from spambots. You need JavaScript enabled to view it.
  • Sun - Fri 8:00 - 20:30
Are we prescribing antibiotics wrong?

Are we prescribing antibiotics wrong?

The message has always been clear: make sure to finish your full course of antibiotics. Or else? Risk the development of antibiotic resistance - a...
Outsourcing Clinical Trials Outside of the US

Outsourcing Clinical Trials Outside of the US

Outsourcing clinical trials has been a subject of both controversy and relevance in the pharmaceutical community. It is an important part of drug...
Regulators And Standards Groups Take Steps To Address Emerging Technologies In Biopharma

Regulators And Standards Groups Take Steps To Address Emerging Technologies In Biopharma

Last year was a banner year for new drugs, with 46 new molecular entities approved by the FDA, compared to 22 in 2016. 2017 also saw the approval of...
Two-dimensional liquid chromatography with multiple heart-cutting

Two-dimensional liquid chromatography with multiple heart-cutting

Two-dimensional liquid chromatography (2D-LC) has obtained increasing focus over the past two decades. At LEO Pharma, we continuously evaluate new...
Understanding Pharmaceutical Logistics Validation in a Dynamic Environment

Understanding Pharmaceutical Logistics Validation in a Dynamic Environment

Applying validation standards to bio/pharmaceutical logistics, the science of transporting bio/analytical, clinical and manufactured product, is an...
Are we prescribing antibiotics wrong?
Are we prescribing antibiotics wrong?
Outsourcing Clinical Trials Outside of the US
Outsourcing Clinical Trials Outside of the US
Regulators And Standards Groups Take Steps To Address Emerging Technologies In Biopharma
Regulators And Standards Groups Take Steps To Address Emerging Technologies In Biopharma
Two-dimensional liquid chromatography with multiple heart-cutting
Two-dimensional liquid chromatography with multiple heart-cutting
Understanding Pharmaceutical Logistics Validation in a Dynamic Environment
Understanding Pharmaceutical Logistics Validation in a Dynamic Environment

Latest White Papers

  • Random

Please take note of the following instructions for submitting your Press Releases:


Format for a News /Press Release

News/Press Releases that posted by you(On behalf of your company) must be clear in words and easier for readers to get the details they need in an efficient manner.  So, in the way of submission of your release, you need to be well prepared.

The press release format that we approve includes the following:

  1. Headline:  Please make your headline short (in max. 100 characters) and relevant (make sure to mention the brand/product in headline) shall be in way to attract the attention of readers.
  2. Subhead (optional):  Secondary statement which explains little more about headline – max.300 characters are allowed.
  3. Date & Location:  The date and time of release, and the city where the news/press release is emanate.
  4. Intro Topic paragraph:  Preliminary paragraph of the release that describes who, what, when, where and why; i.e. the facts.
  5. Main Body:  Main paragraphs which provide supporting material and further details (i.e., direct quotes, relevant background information, statistics, etc.) - as well as the Call to Action (e.g., If the release is about an event, Download, Learn More, Purchase, To Attend the event, About speaker and Agenda and ..more)
  6. Source/Company Info:  A short paragraph giving information about the issuing company or organization.
  7. Contact Information:  Media/Press Contact Information at minimum, the name, phone number and email address for the PR or media relations contact who can answer any questions about the release.

 

Make your press release more effective:

Here are some wonderful tips to keep in mind when writing and distributing your news/press release.  We also help you determine what kind of news is really newsworthy.

  • Write in third person; don’t say “I” or “we” unless using this in a direct quote.
  • Make your content to be very brief if you can; in one page, Or better If it is in 500-600 words.
  • Give your point more clearly grab the attention of reader from the start because reader may figure out what the release is about.
  • Make sure to avoid sales languages which may leads to lose credibility in view of readers.
  • Please keep your own opinions out of it.
  • Please be sure to do your own careful review to avoid mistakes/errors.
  • Please make sure to prepare headline, intro and body of content with strong keywords(must be relevant to your product or services)  that online visitors are likelihood to use when searching for news/press release like yours.
  • Create multimedia elements and include them in your release, such as a YouTube video or a series of images.

Latest News

  • Title
  • Most Views
  • Recently Added
  • Ordering
  • Random
Load More
Load More
Dr. Valentin Pavlov led the study.

Acute liver injury (ALI), often triggered by conditions such as acetaminophen overdose, can rapidly ...

 BD Neopak(TM) XtraFlow(TM) 5.5mL Glass Prefillable Syringe

BD a leading global medical technology company, and Ypsomed, a leading developer of injection ...

BHV-1400 Directly Targets the Disease-Driver of IgA Nephropathy

Biohaven Ltd. a global clinical-stage biopharmaceutical company focused on the discovery, ...

Aptar's Beat the Blink™ Eye Care Technology

AptarGroup, Inc. a global leader in drug delivery and consumer product dosing, dispensing and ...

Load More
Load More
Load More

Latest Updates

Johnson & Johnson a worldwide leader in multiple myeloma therapies, announced that the U.S. Food and Drug Administration (FDA) approved TECVAYLI® plus DARZALEX FASPRO® (daratumumab and ...

Johnson & Johnson a worldwide leader in multiple myeloma therapies, announced that the U.S. Food and Drug Administration (FDA) approved TECVAYLI® plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) who have ...

BD a leading global medical technology company, announced it has obtained CE Marking for the Revello™ Vascular Covered Stent, a next-generation endovascular solution for the treatment of ...

BD a leading global medical technology company, announced it has obtained CE Marking for the Revello™ Vascular Covered Stent, a next-generation endovascular solution for the treatment of atherosclerotic lesions in the common and external iliac arteries.

This advancement arrives at a pivotal ...

Parnell announced the launch of Pentobarbital Sodium and Phenytoin Sodium Euthanasia Solution, a Class III controlled veterinary product formulated for humane, painless, and rapid euthanasia of dogs, ...

Parnell announced the launch of Pentobarbital Sodium and Phenytoin Sodium Euthanasia Solution, a Class III controlled veterinary product formulated for humane, painless, and rapid euthanasia of dogs, available in 100 mL multi‑dose vials.

Designed for clinical reliability and ease of ...

Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, announced the launch of Diphenhydramine Hydrochloride Injection, USP in the United States.

The ...

Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, announced the launch of Diphenhydramine Hydrochloride Injection, USP in the United States.

The product Is the generic equivalent of BENADRYL®, as approved by the U.S. Food and Drug Administration, ...

Otsuka Medical Devices Co., Ltd. and Otsuka Pharmaceutical Co., Ltd. (Otsuka Pharmaceutical) announce that the Paradise™ Ultrasound Renal Denervation (uRDN) system is covered by National Health ...

Otsuka Medical Devices Co., Ltd. and Otsuka Pharmaceutical Co., Ltd. (Otsuka Pharmaceutical) announce that the Paradise™ Ultrasound Renal Denervation (uRDN) system is covered by National Health Insurance system in Japan, effective March 1. Following the inception of insurance coverage, Otsuka ...

Vetter, one of the world's leading pharmaceutical service providers for the production of injectable drugs, has confirmed its plans to build a state-of-the-art production facility in the Saarland ...

Vetter, one of the world's leading pharmaceutical service providers for the production of injectable drugs, has confirmed its plans to build a state-of-the-art production facility in the Saarland region of southwest Germany.

This strategic investment marks a significant milestone in the ...